StocktoriaDermata Therapeutics, Inc. DRMA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M |
| Net income | -$7.6M | -$12.3M | -$7.8M | -$9.6M | -$7.9M |
| Operating cash flow | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M |
| Total assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M |
| Total liabilities | $1.6M | $2.0M | $1.6M | $922,634 | $1.5M |
| Shareholders' equity | $6.2M | $1.6M | $6.4M | $6.0M | $10.1M |
| Ratios | |||||
| Return on assets | -96.1% | -347.7% | -97.7% | -138.4% | -68.0% |
| Return on equity | -121.5% | -787.1% | -122.7% | -159.6% | -78.2% |
| Current ratio | — | — | — | — | 7.66 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001853816 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.